Literature DB >> 11599023

Analysis of antibodies of known structure suggests a lack of correspondence between the residues in contact with the antigen and those modified by somatic hypermutation.

M C Ramirez-Benitez1, J C Almagro.   

Abstract

Forty unique murine antibody-antigen complexes determined at 2.5 A or less resolution are analyzed to determine whether the residues in direct contact with the antigen are modified by somatic hypermutation. This was done by taking advantage of the recent characterization of the pool of Vkappa germline genes of the mouse. The average number of residues in contact with the antigen in the V(L) gene, which contains the CDRL-1, CDRL-2, and all but one residue of CDRL-3, was six. The average number of somatic mutations was similar (around five). However, as many as 53% of the antibodies did not show somatic replacements of residues in contact with the antigen. Another 28% had only one. Overall, the frequency of antibodies with increasing number of somatic replacements in residues in contact with the antigen decreased exponentially. A possible explanation of this finding is that mutations in the contacting residues have an adverse effect on the antigen-antibody interaction. This implies that most of the observed mutations are those remaining after negative (purifying) selection. Therefore, efficient strategies of site-directed mutagenesis to improve the affinity of antibodies should be focused on residues other than those directly interacting with the antigen. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599023     DOI: 10.1002/prot.1140

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  10 in total

1.  Functional mapping of the anti-idiotypic antibody anti-TS1 scFv using site-directed mutagenesis and kinetic analysis.

Authors:  Ann Erlandsson; Patrik Holm; Rozbeh Jafari; Torgny Stigbrand; Birgitta E Sundström
Journal:  MAbs       Date:  2010 Nov-Dec       Impact factor: 5.857

2.  Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection.

Authors:  Biplab Bose; Subrata Sinha
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

3.  Probing a protein-protein interaction by in vitro evolution.

Authors:  George Thom; Alexis C Cockroft; Andrew G Buchanan; Cathy Joberty Candotti; E Suzanne Cohen; David Lowne; Phill Monk; Celia P Shorrock-Hart; Lutz Jermutus; Ralph R Minter
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

4.  Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Authors:  Christy A Thomson; Steve Bryson; Gary R McLean; A Louise Creagh; Emil F Pai; John W Schrader
Journal:  EMBO J       Date:  2008-09-04       Impact factor: 11.598

5.  Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.

Authors:  Mohammed M Al Qaraghuli; Soumya Palliyil; Gillian Broadbent; David C Cullen; Keith A Charlton; Andrew J Porter
Journal:  BMC Biotechnol       Date:  2015-10-24       Impact factor: 2.563

6.  Natural and man-made V-gene repertoires for antibody discovery.

Authors:  William J J Finlay; Juan C Almagro
Journal:  Front Immunol       Date:  2012-11-15       Impact factor: 7.561

7.  In Vitro Evolution of Antibodies Inspired by In Vivo Evolution.

Authors:  Helena Persson; Ufuk Kirik; Linnea Thörnqvist; Lennart Greiff; Fredrik Levander; Mats Ohlin
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

8.  Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site.

Authors:  Brett A McKinney; Nicole L Kallewaard; James E Crowe; Jens Meiler
Journal:  Immunome Res       Date:  2007-09-18

9.  Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules.

Authors:  Laura von Schantz; Fredrika Gullfot; Sebastian Scheer; Lada Filonova; Lavinia Cicortas Gunnarsson; James E Flint; Geoffrey Daniel; Eva Nordberg-Karlsson; Harry Brumer; Mats Ohlin
Journal:  BMC Biotechnol       Date:  2009-10-31       Impact factor: 2.563

Review 10.  Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.

Authors:  Juan C Almagro; Tracy R Daniels-Wells; Sonia Mayra Perez-Tapia; Manuel L Penichet
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.